Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin

JM216, an oral platinum drug entering into phase III clinical trial, exhibited comparable cytotoxicity to cisplatin in three human ovarian carcinoma cell lines: the sensitive (CH1), acquired resistant (CH1cisR) and intrinsically resistant (SKOV-3). Platinum accumulation and binding to DNA were simil...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Neill, C F, Koberle, B, Masters, J R W, Kelland, L R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362973/
https://www.ncbi.nlm.nih.gov/pubmed/10604725
http://dx.doi.org/10.1038/sj.bjc.6694381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362973/
https://www.ncbi.nlm.nih.gov/pubmed/10604725
http://dx.doi.org/10.1038/sj.bjc.6694381

Ejemplares similares